cemka > Publications > Pharmaco-Economics

Sort publications on year

  • Pharmaco-Economics

    Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease

    RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FORETTE F

    J Geriatr Psychiatry Neurol ; 16(3):140-145

  • Pharmaco-Economics

    Patients with Alzheimer’s disease living at home in France : costs and consequences of the disease

    RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FLORETTE F

    J Geriatr Psychiatry Neurol ; 16(3):140-145

  • Pharmaco-Economics

    Cost-effectiveness of interferon-α2 as adjuvant therapy in malignant melanoma

    LAFUMA A, Grob JJ

    Expert Opin Pharmacother ; 4(3):343-349

  • Pharmaco-Economics

    Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection

    PECHEVIS M, KHOSHNOOD B, BUTEAU L, DURAND I, PIQUARD Y, LAFUMA A

    Vaccine ; 21: 3556-3564

  • Pharmaco-Economics

    Cost and effectiveness of brinzolamide versus dorzolamide in current practice : an analysis based on the UK-GPRD database

    DESCHASEAUX-VOINET C, LAFUMA A, BERDEAUX G

    Journal of Medical Economics ; 6 :69-78

  • Pharmaco-Economics

    Comparaison coût-efficacité de l’imiquimod et de la podophyllotoxine dans le traitement du condylome acuminé externe en France

    LAFUMA A, MONSONEGO J, MOYAL-BARRACCO M, PRIBIL C

    Ann Dermatol Venereol ; 130(8-9):731-736

  • Pharmaco-Economics

    A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer

    LEJEUNE C, ARVEUX P, DANCOURT V, FAGNANI F, BONITHON -KOPP C, FAIVRE J

    Eur J Cancer Prev ; 12(1): 77-84

  • Pharmaco-Economics

    The Value of Economic Modeling Studies in the Evaluation of Treatment Strategies for Multiple Sclerosis

    DETOURNAY B

    Value Health ; 5(1):1-2

  • Pharmaco-Economics

    Les enjeux médico-économiques du diabète

    FAGNANI F

    Les enjeux de l'Innovation ; 71-80

  • Pharmaco-Economics

    Economic evaluation of vaccination programmes: a Consensus Statement Focusing on Viral Hepatitis

    BEUTELS P, EDMUNDS WJ, ANTONANZAS F, DE WIT GA, EVANS D, FEILDEN R, FENDRICK AM, GINSBERG GM, GLICK HA, MAST E, PECHEVIS M, VAN DOORSLAER E, BA, VAN HOUT

    Pharmacoeconomics ; 20(1):1-7

  • Pharmaco-Economics

    Démences : Aspects économiques

    FAGNANI F

    Traité de neurologie : Démences ; Editions Doin (Groupe Liaisons) ; Chapitre 65: 493-497

  • Pharmaco-Economics

    Coût-efficacité du contrôle strict de la glycémie par la metformine chez des diabétiques de type 2 présentant une surcharge pondérale

    PALMER AJ, SENDI PP, ROZE S, COMTE S, CABRIERES L, LAFUMA A, SPINAS GA

    Journal d'Economie Médicale ; 20(1): 45-58

  • Pharmaco-Economics

    Cost-effectiveness of olopatadine in seasonal allergic conjunctivitis treatment

    LAFUMA A, SMITH AF

    Expert Rev Pharmacoecon Outcomes Res ; 2(6): 89-94

  • Pharmaco-Economics

    Cost of Care for Inpatients with Community -Acquired Intra-Abdominal Infections

    CATTAN P, YIN DD, SARFATI E, LYU R, DE ZELICOURT M, FAGNANI F

    Eur J Clin Microbiol Infect Dis ; 21: 787-793

  • Pharmaco-Economics

    Cost and effectiveness of ciprofloxacin + hydrocortisone versus neomycin + polymyxin B + hydrocortisone in France for the treatment of acute otitis externa

    LAFUMA A, FAGNANI F, BERDEAUX G

    Journal of Medical Economics ; 2002;5:11-23